Sarah Cannon

How We’re Advancing Blood Cancer Care Through Cellular Therapy

Issue link: http://sarahcannon.uberflip.com/i/1190396

Contents of this Issue

Navigation

Page 1 of 1

140+ Patients With CAR T-Cell Therapy to Date Across Commercial and Clinical care settings 844.482.4812 asksarah@sarahcannon.com For more information: Learn more about us at sarahcannon.com/bloodcancernetwork 1122/19SCB29-4/R4 Immune Cell Therapy Committees • Coordination and Standardization of Research Processes Across Centers for Both Blood Cancer and Solid Tumor Indicators • Local Committees Comprised of Site Transplant, Nursing, Research Staff, and Physicians Meet Monthly at Each Sarah Cannon Blood Cancer Network Center • Local Committees Report to Sarah Cannon Immune Effector Cell Therapy Leadership Monthly Studies Open in: • Multiple Myeloma • Diffuse Large B-Cell Lymphoma • Mantle Cell Lymphoma • Indolent Non-Hodgkin Lymphoma • B-Cell Non-Hodgkin Lymphoma • ALL • CLL/SLL • AML/MDS • Multi Indication Solid Tumor • Sarcoma • Melanoma • Non-Small Cell Lung Cancer • CRISPR CD34+ Gene Therapy Sickle Cell Disease • Biomarker Driven Basket Trial Commercial CAR T-Cell Therapy • 5 Programs in U.S. Certified by Novartis • 5 Programs in U.S. Certified by Kite • 1 Program in UK in Certified by Gilead Immune Effector Cell Therapy Studies Activated Since December 2015 30+ How We're Advancing Blood Cancer Care Through Cellular Therapy Immune Effector Cell Therapy

Articles in this issue

Links on this page

view archives of Sarah Cannon - How We’re Advancing Blood Cancer Care Through Cellular Therapy